Vasopressin for Vasoplegic Shock Market to Hit $2,657.9 Mn by 2027; Stoked by Increasing Prevalence of Sepsis Globally

The global vasopressin for vasoplegic shock market size is expected to reach USD 2,657.9 million by 2027. This is attributable to the increasing prevalence of sepsis that is expected to drive the demand for advanced vasopressin for vasoplegic shock treatment globally. This information is published by Fortune Business Insights, in its latest report, titled, “Vasopressin for Vasoplegic Shock Market Size, Share & COVID-19 Impact Analysis, By Application (Sepsis, Post Cardiac Surgery, and Others) Regional Forecast, 2020-2027.” The report further mentions that the market stood at USD 890.9 million in 2019 and is likely to exhibit a remarkable CAGR of 14.8% between 2020 and 2027.

AMOMED Pharma to Offer Severe COVID-19 Treatment Drugs to Brighten Their Market Prospects

In April 2020, AMOMED Pharma announced the development of medicinal products to treat patients going through septic shock amid COVID-19 at the intensive care units. The septic shock is a severe lung disorder that is considered to be a serious implication amongst the novel coronavirus patients. The company is the only pharmaceutical company that has received approval from the European Union to use arginine vasopressin drugs to treat the patients in septic shock amid the global pandemic.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/vasopressin-for-vasoplegic-shock-market-104065

The pandemic has led to a tremendous strain on healthcare services, and major companies such as AMOMED Pharma are taking enormous efforts to develop effective vasopressin for vasoplegic shock treatment models.

Increasing Prevalence of Sepsis to Promote Growth

According to the National Institute for Health and Care Excellence (NICE), it is estimated that there are around 123,000 cases of sepsis in England every year that further claims about 36,900 lives in the country. The increasing prevalence of sepsis is expected to drive the demand for advanced vasopressin for vasoplegic shock treatment methods globally. Additionally, the manufacturers are focusing on investing in R&D activities to develop innovative vasopressin drugs that will bode well for the growth of the global market during the forecast period.

Key Players Such as Endo International plc & AMOMED Pharma Focus on Product Innovation to Leverage Lucrative Market Opportunities

The global vasopressin for vasoplegic shock market is fragmented by the presence of major companies such as AMOMED Pharma, and Endo International plc, among others. These companies are leveraging the lucrative opportunities by focusing on developing innovative vasopressin for treatment procedures during the forecast period. The other key players are adopting strategies such as partnership, facility expansion, and collaboration to maintain their presence in the highly competitive global marketplace.

List of the Companies Profiled in the Market:

• Endo International plc (Dublin, Ireland)
• AMOMED Pharma (Vienna, Austria)
• La Jolla Pharmaceutical Company (California, U.S.)
• Pfizer Inc. (New York, U.S.)
• Ferring Pharmaceuticals (Saint-Prex, Switzerland)
• Fresenius Kabi Canada (Toronto, Canada)
• Astellas Pharma (Tokyo, Japan)
• Eagle Pharmaceuticals, Inc. (New Jersey, U.S.)
• Others

Further Report Findings:

• North America is expected to remain at the forefront and hold the highest position in the global market during the forecast period. This is attributable to the rising cases of cardiac surgeries that augment the demand for advanced vasopressin for vasoplegic shock treatment procedures in the region.
• The market in Asia-Pacific is expected to showcase an exponential growth owing to the growing focus by manufacturers to penetrate the lucrative economies in the region between 2020 and 2027.
• The post cardiac segment, based on application, held about 25.2% market share in 2019 and is likely to gain momentum during the forecast period. This is ascribable to factors such as the rising number of cardiac surgeries that propel the demand for new treatment models for vasoplegic shock across the globe.

Table of Segmentation: